Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells

被引:48
|
作者
He, Xiaocui [1 ,2 ]
Klaesener, Kathrin [1 ,2 ]
Iype, Joseena M. [1 ,3 ]
Becker, Martin [1 ,4 ]
Maity, Palash C. [1 ,3 ]
Cavallari, Marco [1 ]
Nielsen, Peter J. [2 ]
Yang, Jianying [1 ,2 ]
Reth, Michael [1 ,2 ]
机构
[1] Univ Freiburg, Biol 3, BIOSS Ctr Biol Signaling Studies, Fac Biol,Dept Mol Immunol, Freiburg, Germany
[2] Max Planck Inst Immunobiol & Epigenet, Freiburg, Germany
[3] Uni Hosp Ulm, Inst Immunol, Ulm, Germany
[4] Helmholtz Zentrum Munchen, Munich, Germany
来源
EMBO JOURNAL | 2018年 / 37卷 / 11期
基金
欧洲研究理事会;
关键词
B-cell antigen receptor; Burkitt lymphoma; Cas9; CRISPR; survival signal; tumor fitness; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN RECEPTOR; IG-ALPHA; IMMUNE-RESPONSE; BAFF-R; BETA; IMMUNOGLOBULIN; SURVIVAL; PROTEIN; MICE;
D O I
10.15252/embj.201797980
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Expression of the B-cell antigen receptor (BCR) is essential not only for the development but also for the maintenance of mature B cells. Similarly, many B-cell lymphomas, including Burkitt lymphoma (BL), require continuous BCR signaling for their tumor growth. This growth is driven by immunoreceptor tyrosine-based activation motif (ITAM) and PI3 kinase (PI3K) signaling. Here, we employ CRISPR/Cas9 to delete BCR and B-cell co-receptor genes in the human BL cell line Ramos. We find that Ramos B cells require the expression of the BCR signaling component Ig (CD79b), and the co-receptor CD19, for their fitness and competitive growth in culture. Furthermore, we show that in the absence of any other BCR component, Ig can be expressed on the B-cell surface, where it is found in close proximity to CD19 and signals in an ITAM-dependent manner. These data suggest that Ig and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B cells
    Fouillit, M
    Joubert-Caron, R
    Poirier, F
    Bourin, P
    Monostori, E
    Levi-Strauss, M
    Raphael, M
    Bladier, D
    Caron, M
    GLYCOBIOLOGY, 2000, 10 (04) : 413 - 419
  • [42] Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b
    Seon, Ben K.
    Okazaki, Morihiro
    Duzen, Jill
    Matsuno, Fumihiko
    Goey, Andrew K. L.
    Maguire, Orla
    LEUKEMIA RESEARCH, 2024, 136
  • [43] CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
    Sonanini, Dominik
    Schwenck, Johannes
    Blaess, Simone
    Schmitt, Julia
    Maurer, Andreas
    Ehrlichmann, Walter
    Ritter, Malte
    Skokowa, Julia
    Kneilling, Manfred
    Jung, Gundram
    Fend, Falko
    Krost, Simon
    Seitz, Christian M.
    Lang, Peter
    Reischl, Gerald
    Handgretinger, Rupert
    Fougere, Christian la
    Pichler, Bernd J.
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [44] Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia
    Astsaturov, IA
    Matutes, E
    Morilla, R
    Seon, BK
    Mason, DY
    Farahat, N
    Catovsky, D
    LEUKEMIA, 1996, 10 (05) : 769 - 773
  • [45] Regulation of CD19 surface expression in human B cells by CD81
    Levy, Shoshana
    Kuo, Chiung-Chi
    Sagi, Yael
    Chen, Homer
    Kela-Madar, Neta
    van Zelm, Menno
    van Dongen, Jacques
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [46] Distinct CD81 domains control CD19 maturation in B cells
    Shoham, T
    Rajapaksa, R
    Kuo, CC
    Haimovich, J
    Levy, S
    FASEB JOURNAL, 2005, 19 (04): : A881 - A881
  • [47] Somatic hypermutation of the B cell receptor genes B29 (Igβ, CD79b) and mb1 (Igα, CD79a)
    Gordon, MS
    Kanegai, CM
    Doerr, JR
    Wall, R
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) : 4126 - 4131
  • [48] T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16
    Lisa M. Pörtner
    Kathrin Schönberg
    Maryam Hejazi
    Daniela Brünnert
    Frank Neumann
    Lars Galonska
    Uwe Reusch
    Melvyn Little
    Rainer Haas
    Markus Uhrberg
    Cancer Immunology, Immunotherapy, 2012, 61 : 1869 - 1875
  • [49] Regulation of B cell activity by inducing specific autoimmune response against CD79b
    Chen, LYY
    Sheu, JJC
    Chang, TW
    FASEB JOURNAL, 2000, 14 (06): : A1123 - A1123
  • [50] CD81-Dependent Trafficking of CD19: Restoration of CD19 Surface Expression in Human B Cells Harboring A CD81 Mutation
    Levy, Shoshana
    Kuo, Chiung-Chi
    Sagi, Yael
    Chen, Homer
    Kela-Madar, Neta
    van Zelm, Menno
    van Dongen, Jacques J. M.
    BLOOD, 2012, 120 (21)